Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.21
+$0.08 · +7.08%
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Regular session
$1.21
+$0.08 · +7.08%
Regular session · ET · Market data may be delayed.
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Day range
Current $1.21
52-week range
Current $1.21
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
53
Mixed
Risk
66
High Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Day range
Current $1.21
52-week range
Current $1.21
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 10.28M USD | 5.23M USD | 10.25M USD | 15.92M USD | 17.82M USD |
| Selling, general, and administrative | — | 10.28M USD | 8.26M USD | 4.76M USD | 1.15M USD |
| Operating expenses | 21.13M USD | 15.79M USD | 22.73M USD | 17.93M USD | 36.93M USD |
| Interest income | 19K USD | 814K USD | 1.46M USD | — | — |
| Interest expense | 18K USD | 6K USD | 12.64K USD | 8.6K USD | 237.41K USD |
| Depreciation and amortization | 234K USD | 124K USD | 96K USD | 51K USD | 141K USD |
| Operating income | −21.13M USD | −15.79M USD | −22.73M USD | −17.93M USD | −36.93M USD |
| Net income | −18.43M USD | −11.86M USD | −22.36M USD | −18.92M USD | −31.59M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 21, 2021 | 1:2 | — | — |
Stock split | Jul 31, 2020 | 2,499:1,000 | — | — |
Stock split | Oct 29, 2019 | 2:1 | — | — |
Effective Oct 21, 2021
1:2
Effective Jul 31, 2020
2,499:1,000
Effective Oct 29, 2019
2:1
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
